Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label Study of Autologous Mutant KRAS-redirected T-cell Receptor Cells (TCR1020-CD8)

NCT06707896 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT06707896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06707896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label Study of Autologous Mutant KRAS-redirected T-cell Receptor Cells (TCR1020-CD8)
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Withdrawn
Start date
June 1, 2025
Completion date
February 1, 2044
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, metastatic pancreatic adenocarcinoma